ANPCF Stock — ANGLE plc

ANGLE plc (ANPCF)

Updated October 9, 2026.

ANPCF is a Stock. Total return is -98.7% over the past 12.7 years, 525.7 points behind SPY at 427.0%.

CelLBxHealth plc (formerly ANGLE plc) develops cancer diagnostic products based on its Parsortix platform technology, which analyzes circulating tumor cells in blood samples to provide real-time multiomic insights. The company offers diagnostic kits, laboratory services, and custom assays for cancer detection and characterization, supported by partnerships with organizations including BioView Ltd and The Royal Marsden NHS Foundation Trust. The company does not currently distribute to shareholders.

ANPCF performance versus SPY

Price and return data through 2026-10-09.

Total return is -98.7% over the past 12.7 years, 525.7 points behind SPY at 427.0%. Over the past year its total return — price change plus distributions reinvested — is -58.3%. Its deepest 1-year drawdown was 78.4%.

ANPCF key facts

Asset type

Stock

Asset class

Equity

Inception date

01/23/2014

Distribution frequency

None

Last close

$0.02 (stale; as of 2026-10-09)

Market cap

$22,614,413

Average volume

0.0

Beta

0.601

Payout ratio

0.0%

EPS

$-0.05

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ANPCF risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 78.4%.

Who may consider ANPCF — and who may not

It is a weaker fit for investors who need monthly cash flow (ANPCF does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ANPCF

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions